Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imiquimod + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- University of Washington
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical, Intravenous
01
Overview
Imiquimod + nab-paclitaxel is a combination therapy consisting of topical imiquimod (a 5% cream) and systemic nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Imiquimod is a synthetic immune response modifier that acts as an agonist of toll-like receptor 7 (TLR-7), stimulating innate and adaptive immune responses, including the activation of CD8+ T cells and production of interferon-gamma. Nab-paclitaxel is a chemotherapeutic agent where paclitaxel is bound to albumin nanoparticles, enhancing its delivery to tumors; it disrupts microtubule function leading to cell cycle arrest and apoptosis in cancer cells. This combination has been investigated primarily for treatment-refractory cutaneous metastases from breast cancer, aiming to leverage both direct cytotoxic effects and immunomodulation for improved tumor regression[1][3][4].
- Other names
- imiquimod plus nab-paclitaxelimiquimod + albumin-bound paclitaxelimiquimod + Abraxane
02
Targets
TUBB (Tubulin (alpha and beta subunits))TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on imiquimod + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imiquimod + nab-paclitaxel.